BIRC5 and cancer: Cancer therapeutics targeting Birc5/survivin include survivin‐partner protein interaction inhibitors, survivin homodimerization inhibitors, survivin gene transcription inhibitors, survivin mRNA inhibitors, and survivin immunotherapy.44